These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 37349736)

  • 1. Characterization and evaluation of gene fusions as a measure of genetic instability and disease prognosis in prostate cancer.
    Schimmelpfennig C; Rade M; Füssel S; Löffler D; Blumert C; Bertram C; Borkowetz A; Otto DJ; Puppel SH; Hönscheid P; Sommer U; Baretton GB; Köhl U; Wirth M; Thomas C; Horn F; Kreuz M; Reiche K
    BMC Cancer; 2023 Jun; 23(1):575. PubMed ID: 37349736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A reliable transcriptomic risk-score applicable to formalin-fixed paraffin-embedded biopsies improves outcome prediction in localized prostate cancer.
    Rade M; Kreuz M; Borkowetz A; Sommer U; Blumert C; Füssel S; Bertram C; Löffler D; Otto DJ; Wöller LA; Schimmelpfennig C; Köhl U; Gottschling AC; Hönscheid P; Baretton GB; Wirth M; Thomas C; Horn F; Reiche K
    Mol Med; 2024 Feb; 30(1):19. PubMed ID: 38302875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ProstaTrend-A Multivariable Prognostic RNA Expression Score for Aggressive Prostate Cancer.
    Kreuz M; Otto DJ; Fuessel S; Blumert C; Bertram C; Bartsch S; Loeffler D; Puppel SH; Rade M; Buschmann T; Christ S; Erdmann K; Friedrich M; Froehner M; Muders MH; Schreiber S; Specht M; Toma MI; Benigni F; Freschi M; Gandaglia G; Briganti A; Baretton GB; Loeffler M; Hackermüller J; Reiche K; Wirth M; Horn F
    Eur Urol; 2020 Sep; 78(3):452-459. PubMed ID: 32631745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A TMEFF2-regulated cell cycle derived gene signature is prognostic of recurrence risk in prostate cancer.
    Georgescu C; Corbin JM; Thibivilliers S; Webb ZD; Zhao YD; Koster J; Fung KM; Asch AS; Wren JD; Ruiz-Echevarría MJ
    BMC Cancer; 2019 May; 19(1):423. PubMed ID: 31060542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Random forest-based modelling to detect biomarkers for prostate cancer progression.
    Toth R; Schiffmann H; Hube-Magg C; Büscheck F; Höflmayer D; Weidemann S; Lebok P; Fraune C; Minner S; Schlomm T; Sauter G; Plass C; Assenov Y; Simon R; Meiners J; Gerhäuser C
    Clin Epigenetics; 2019 Oct; 11(1):148. PubMed ID: 31640781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling.
    Klein EA; Cooperberg MR; Magi-Galluzzi C; Simko JP; Falzarano SM; Maddala T; Chan JM; Li J; Cowan JE; Tsiatis AC; Cherbavaz DB; Pelham RJ; Tenggara-Hunter I; Baehner FL; Knezevic D; Febbo PG; Shak S; Kattan MW; Lee M; Carroll PR
    Eur Urol; 2014 Sep; 66(3):550-60. PubMed ID: 24836057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene signatures ESC, MYC and ERG-fusion are early markers of a potentially dangerous subtype of prostate cancer.
    Rye MB; Bertilsson H; Drabløs F; Angelsen A; Bathen TF; Tessem MB
    BMC Med Genomics; 2014 Aug; 7():50. PubMed ID: 25115192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a candidate prognostic gene signature by transcriptome analysis of matched pre- and post-treatment prostatic biopsies from patients with advanced prostate cancer.
    Rajan P; Stockley J; Sudbery IM; Fleming JT; Hedley A; Kalna G; Sims D; Ponting CP; Heger A; Robson CN; McMenemin RM; Pedley ID; Leung HY
    BMC Cancer; 2014 Dec; 14():977. PubMed ID: 25519703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of two gene panels for prostate cancer diagnosis and patient risk stratification.
    Xiao K; Guo J; Zhang X; Feng X; Zhang H; Cheng Z; Johnson H; Persson JL; Chen L
    Tumour Biol; 2016 Aug; 37(8):10115-22. PubMed ID: 26820133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High alpha-methylacyl-CoA racemase (AMACR) is associated with ERG expression and with adverse clinical outcome in patients with localized prostate cancer.
    Box A; Alshalalfa M; Hegazy SA; Donnelly B; Bismar TA
    Tumour Biol; 2016 Sep; 37(9):12287-12299. PubMed ID: 27271990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrative clinical transcriptome analysis reveals TMPRSS2-ERG dependency of prognostic biomarkers in prostate adenocarcinoma.
    Gerke JS; Orth MF; Tolkach Y; Romero-Pérez L; Wehweck FS; Stein S; Musa J; Knott MML; Hölting TLB; Li J; Sannino G; Marchetto A; Ohmura S; Cidre-Aranaz F; Müller-Nurasyid M; Strauch K; Stief C; Kristiansen G; Kirchner T; Buchner A; Grünewald TGP
    Int J Cancer; 2020 Apr; 146(7):2036-2046. PubMed ID: 31732966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel fusion transcripts associate with progressive prostate cancer.
    Yu YP; Ding Y; Chen Z; Liu S; Michalopoulos A; Chen R; Gulzar ZG; Yang B; Cieply KM; Luvison A; Ren BG; Brooks JD; Jarrard D; Nelson JB; Michalopoulos GK; Tseng GC; Luo JH
    Am J Pathol; 2014 Oct; 184(10):2840-9. PubMed ID: 25238935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stromal Gene Expression is Predictive for Metastatic Primary Prostate Cancer.
    Mo F; Lin D; Takhar M; Ramnarine VR; Dong X; Bell RH; Volik SV; Wang K; Xue H; Wang Y; Haegert A; Anderson S; Brahmbhatt S; Erho N; Wang X; Gout PW; Morris J; Karnes RJ; Den RB; Klein EA; Schaeffer EM; Ross A; Ren S; Sahinalp SC; Li Y; Xu X; Wang J; Wang J; Gleave ME; Davicioni E; Sun Y; Wang Y; Collins CC
    Eur Urol; 2018 Apr; 73(4):524-532. PubMed ID: 28330676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Biopsy-based 17-gene Genomic Prostate Score as a Predictor of Metastases and Prostate Cancer Death in Surgically Treated Men with Clinically Localized Disease.
    Van Den Eeden SK; Lu R; Zhang N; Quesenberry CP; Shan J; Han JS; Tsiatis AC; Leimpeter AD; Lawrence HJ; Febbo PG; Presti JC
    Eur Urol; 2018 Jan; 73(1):129-138. PubMed ID: 28988753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TMEM45B is a novel predictive biomarker for prostate cancer progression and metastasis.
    Luo F; Yang K; Wang YZ; Lin D
    Neoplasma; 2018 Sep; 65(5):815-821. PubMed ID: 30249106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GBX2 Methylation Is a Novel Prognostic Biomarker and Improves Prediction of Biochemical Recurrence Among Patients with Prostate Cancer Negative for Intraductal Carcinoma and Cribriform Architecture.
    Jeyapala R; Savio AJ; Olkhov-Mitsel E; Kamdar S; Zhao F; Cuizon C; Liu RSC; Zlotta A; Fleshner N; van der Kwast T; Bapat B
    Eur Urol Oncol; 2019 May; 2(3):231-238. PubMed ID: 31200836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene signatures predict biochemical recurrence-free survival in primary prostate cancer patients after radical therapy.
    Su Q; Liu Z; Chen C; Gao H; Zhu Y; Wang L; Pan M; Liu J; Yang X; Tian J
    Cancer Med; 2021 Sep; 10(18):6492-6502. PubMed ID: 34453418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prognostic and predictive value of TMPRSS2-ERG gene fusion and ERG protein expression in prostate cancer biopsies.
    Berg KD
    Dan Med J; 2016 Dec; 63(12):. PubMed ID: 27910803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting biochemical-recurrence-free survival using a three-metabolic-gene risk score model in prostate cancer patients.
    Zhao Y; Tao Z; Li L; Zheng J; Chen X
    BMC Cancer; 2022 Mar; 22(1):239. PubMed ID: 35246070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.